• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Open Pain Journal >Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib onthe 1% Formalin Test in Rats
【24h】

Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib onthe 1% Formalin Test in Rats

机译：1％福尔马林试验对利多卡因和卢米拉昔布之间的外周协同作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It has been shown that the association of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesicagents can increase their antinociceptive activity, allowing the use of lower doses and thus limiting side effects. Therefore,the aim of the present study was to examine the possible pharmacological interaction between lumiracoxib and lidocaineat the local peripheral level in the rat using the 1% formalin test and isobolographic analysis. Lumiracoxib, lidocaine orfixed-dose ratio (1:1) lumiracoxib-lidocaine combinations were administered locally in the formalin-injured paw and theantinociceptive effect was evaluated. All treatments produced a dose-dependent antinociceptive effect. ED40 values wereestimated for the individual drugs and an isobologram was constructed. The derived theoretical ED40 for the lumiracoxiblidocainecombination was 599.3 ± 58.8 μg/paw, being significantly higher than the actually observed experimental ED40value, 393.6 ± 39.7 μg/paw. This result correspond to a synergistic interaction between lumiracoxib and lidocaine at thelocal peripheral level, potency being about one and half times higher with regard to that expected from the addition of theeffects of the individual drugs. Data suggest that low doses of the lumiracoxib-lidocaine combination can interactsynergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for theclinical treatment of procedural or inflammatory pain.
机译：已经显示非甾体抗炎药（NSAID）与止痛药的结合可以增加其抗伤害感受活性，从而允许使用较低剂量并因此限制了副作用。因此，本研究的目的是使用1％福尔马林测试和等效线描记法分析在大鼠的局部外周水平检查鲁美昔布和利多卡因之间可能的药理相互作用。 Lumiracoxib，利多卡因或固定剂量比（1：1）的lumiracoxib-利多卡因组合在福尔马林受伤的爪中局部给药，并评估了其镇痛作用。所有治疗均产生剂量依赖性抗伤害感受作用。估计每种药物的ED40值，并绘制等效线图。鲁美考拉利多卡因组合的理论ED40推导值为599.3±58.8μg/ paw，显着高于实际观察到的实验ED40值393.6±39.7μg/ paw。该结果对应于鲁美昔布和利多卡因在局部外周水平上的协同相互作用，相对于单独药物作用的增加所预期的效力，效力约高一半和一半。数据表明，低剂量的卢美考昔-利多卡因组合可以在外周水平协同相互作用，因此这种药物结合可能代表了临床治疗程序性或炎症性疼痛的治疗优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号